US pharmaceutical firms plan to increase list prices on at least 350 branded medicines in 2026, including key Covid vaccines and cancer drug Ibrance, despite pressure from the Trump administration for reductions.
Hot this week
Free News - Where voices unite, stories flourish, and community thrives through open dialogue and meaningful connections.
Get important news delivered directly to your inbox and stay connected!
